©2019 by CBD Research Group. Proudly created with Wix.com

EPILEPSY

Search and Discover

EPILEPSY

1.) Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical  center         

https://www.epilepsybehavior.com/article/S1525-5050(18)30009-X/fulltext

“Consistent with other studies, our retrospective study suggests that artisanal CBD is helpful in the treatment of medically refractory epilepsy [10] with benefits that cannot be credited to interaction with clobazam and increased levels of its active metabolite. These data add additional support for the use of artisanal CBD in the treatment of drug-resistant epilepsy as in our patient population. As has recently been reported, outside of seizure control, CBD use was also associated with increased alertness, improved verbal communication, better social interactions, and better mood, suggesting additional benefits to use of CBD [9].”

 

 

2.) CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience

https://www.seizure-journal.com/article/S1059-1311(16)00005-4/fulltext

“CBD-enriched medical cannabis is a promising treatment for intractable epilepsy.”

“Only minor and infrequent side effects were reported.”

“Epileptic encephalopathies respond better to CBD-enriched medical cannabis.”

 

 

3.) Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study

ttps://www.epilepsybehavior.com/article/S1525-5050(18)30473-6/fulltext

“Of the 132 patients enrolled, 77% remained in the study at 24 months.”

“CBD was associated with sustained reduction in seizure frequency and severity at 24 months.”

“Addition of CBD resulted in a sustained decrease in the adverse events profile.”

 

 

4.) Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175436/

“Add-on CBD reduced median monthly convulsive seizures by 51% and total seizures by 48% at 12 weeks; reductions were similar through 96 weeks.”

 

 

 

5.) Cannabidiol exerts antiepileptic effects by restoring hippocampal interneuron functions in a temporal lobe epilepsy model.​https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5979781/

“Our data suggest that CBD restores excitability and morphological impairments in epileptic models to pre-epilepsy control levels through multiple mechanisms to reinstate normal network function.”

 

 

6.) Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?

https://www.ncbi.nlm.nih.gov/pubmed/29344464

“For the first time, there is now class 1 evidence that adjunctive use of CBD improves seizure control in patients with specific epilepsy syndromes. Based on currently available information, however, it is unclear whether the improved seizure control described in these trials was related to a direct action of CBD, or was mediated by drug interactions with concomitant medications, particularly a marked increased in plasma levels of N-desmethylclobazam, the active metabolite of clobazam.”

 

 

 

7.) Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568670/

“The results suggest that CBD may have beneficial effects on patient Quality of Life, distinct from its seizure-reducing effects; however, further studies in placebo-controlled, double-blind trials are necessary to confirm this finding.”

 

8.) Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex

https://onlinelibrary.wiley.com/doi/full/10.1111/epi.13499

“Although double-blind, placebo-controlled trials are still necessary, these findings suggest that cannabidiol may be an effective and well-tolerated treatment option for patients with refractory seizures in TSC.”

 

9.) Cannabidiol Limits T Cell-Mediated Chronic Autoimmune Myocarditis: Implications to Autoimmune Disorders and Organ Transplantation​

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004721/

“Collectively, our study demonstrates that CBD treatment markedly attenuates autoimmune myocarditis and improves myocardial dysfunction and heart failure primarily by its antiinflammatory and antifibrotic effects”….” These results, coupled with the proven safety of CBD in human clinical trials and its current orphan drug approval by the FDA for different neurological disorders, suggest that it has tremendous therapeutic potential in the therapy of myocarditis with different etiologies and various autoimmune disorders. The latter is also supported by beneficial effects of CBD in preventing graft versus host disease after allogeneic hematopoietic cell transplantation in a recent phase II human study (50), as well as in mice with arthritis (51). Attenuation of the T cell–mediated injury by CBD also suggests that it may have therapeutic utility in management of organ transplantation/rejection.”